CD8A and classic Hodgkin lymphoma: Although this approach enabled an unbiased evaluation of relevant anti‐tumoral immunity in EBV+cHL, ex‐vivo assays are less sensitive than in‐vitro expansion for the detection of low‐frequency EBV‐specific CD8+ T cells 43.